Brainstorm Cell Therapeutics Inc (BCLI)
0.53
-0.02
(-2.75%)
USD |
NASDAQ |
Apr 25, 13:26
Brainstorm Cell Therapeutics Enterprise Value: 35.95M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 35.95M |
| April 23, 2024 | 34.58M |
| April 22, 2024 | 35.61M |
| April 19, 2024 | 35.06M |
| April 18, 2024 | 33.85M |
| April 17, 2024 | 35.66M |
| April 16, 2024 | 34.72M |
| April 15, 2024 | 36.20M |
| April 12, 2024 | 38.61M |
| April 11, 2024 | 38.14M |
| April 10, 2024 | 39.81M |
| April 09, 2024 | 38.51M |
| April 08, 2024 | 48.59M |
| April 05, 2024 | 43.19M |
| April 04, 2024 | 44.83M |
| April 03, 2024 | 45.81M |
| April 02, 2024 | 47.84M |
| April 01, 2024 | 49.27M |
| March 28, 2024 | 37.29M |
| March 27, 2024 | 39.72M |
| March 26, 2024 | 43.67M |
| March 25, 2024 | 43.33M |
| March 22, 2024 | 37.54M |
| March 21, 2024 | 31.41M |
| March 20, 2024 | 33.25M |
| Date | Value |
|---|---|
| March 19, 2024 | 22.94M |
| March 18, 2024 | 21.08M |
| March 15, 2024 | 21.38M |
| March 14, 2024 | 21.09M |
| March 13, 2024 | 21.23M |
| March 12, 2024 | 19.69M |
| March 11, 2024 | 21.12M |
| March 08, 2024 | 21.18M |
| March 07, 2024 | 22.40M |
| March 06, 2024 | 21.16M |
| March 05, 2024 | 22.43M |
| March 04, 2024 | 23.57M |
| March 01, 2024 | 22.22M |
| February 29, 2024 | 20.90M |
| February 28, 2024 | 20.88M |
| February 27, 2024 | 20.66M |
| February 26, 2024 | 20.41M |
| February 23, 2024 | 19.81M |
| February 22, 2024 | 18.69M |
| February 21, 2024 | 17.51M |
| February 20, 2024 | 20.48M |
| February 16, 2024 | 21.30M |
| February 15, 2024 | 22.17M |
| February 14, 2024 | 19.81M |
| February 13, 2024 | 18.96M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.560M
Minimum
Oct 24 2023
530.89M
Maximum
Oct 08 2020
114.81M
Average
89.60M
Median
Jun 10 2022
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.284M |
| Palatin Technologies Inc | 18.43M |
| iBio Inc | 16.49M |
| Theriva Biologics Inc | -13.90M |
| Oragenics Inc | 3.306M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.578M |
| Total Expenses (Quarterly) | 4.804M |
| EPS Diluted (Quarterly) | -0.11 |
| Earnings Yield | -77.36% |